Our mission is to improve the cure rate of patients with PTCL and reduce treatment-related toxicity by developing novel targeted therapy using rationally designed small molecules, antibodies and combination regimens of biologic agents.

For referrals, please contact ayounes@mdanderson.org or Amanda Copeland at ARCopeland@mdanderson.org.